These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 12057714

  • 1. Raloxifene treatment increases plasma levels of beta-endorphin in postmenopausal women: a randomized, placebo-controlled study.
    Neele SJ, Evertz R, Genazzani AR, Luisi M, Netelenbos C.
    Fertil Steril; 2002 Jun; 77(6):1110-7. PubMed ID: 12057714
    [Abstract] [Full Text] [Related]

  • 2. Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial.
    Strickler R, Stovall DW, Merritt D, Shen W, Wong M, Silfen SL.
    Obstet Gynecol; 2000 Sep; 96(3):359-65. PubMed ID: 10960626
    [Abstract] [Full Text] [Related]

  • 3. Raloxifene and hormone replacement therapy increase arachidonic acid and docosahexaenoic acid levels in postmenopausal women.
    Giltay EJ, Duschek EJ, Katan MB, Zock PL, Neele SJ, Netelenbos JC.
    J Endocrinol; 2004 Sep; 182(3):399-408. PubMed ID: 15350182
    [Abstract] [Full Text] [Related]

  • 4. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women.
    Mijatovic V, Netelenbos C, van der Mooren MJ, de Valk-de Roo GW, Jakobs C, Kenemans P.
    Fertil Steril; 1998 Dec; 70(6):1085-9. PubMed ID: 9848300
    [Abstract] [Full Text] [Related]

  • 5. Neuroendocrine effects of raloxifene hydrochloride in postmenopausal women.
    Florio P, Quirici B, Casarosa E, Lombardi I, Luisi M, Genazzani AD, Petraglia F, Genazzani AR.
    Gynecol Endocrinol; 2001 Oct; 15(5):359-66. PubMed ID: 11727358
    [Abstract] [Full Text] [Related]

  • 6. Serum estradiol level and risk of breast cancer during treatment with raloxifene.
    Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA, Multiple Outcomes of Raloxifene Evaluation (MORE) Trial.
    JAMA; 2002 Jan 09; 287(2):216-20. PubMed ID: 11779264
    [Abstract] [Full Text] [Related]

  • 7. Raloxifene reduces impedance to flow within the uterine artery in early postmenopausal women: a 2-year randomized, placebo-controlled, comparative study.
    Post MS, van der Mooren MJ, van Baal WM, Neele SJ, Netelenbos JC, Kenemans P.
    Am J Obstet Gynecol; 2001 Sep 09; 185(3):557-62. PubMed ID: 11568777
    [Abstract] [Full Text] [Related]

  • 8. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, Pajon ER, Wade JL, Dakhil S, Lockhart JB, Wolmark N, Ganz PA.
    JAMA; 2006 Jun 21; 295(23):2742-51. PubMed ID: 16754728
    [Abstract] [Full Text] [Related]

  • 9. A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life.
    Voss S, Quail D, Dawson A, Bäckström T, Aguas F, Erenus M, The HS, Bonnar J, De Geyter C, Hunter M, Nickelsen T, Euralox Investigators Group.
    BJOG; 2002 Aug 21; 109(8):874-85. PubMed ID: 12197366
    [Abstract] [Full Text] [Related]

  • 10. Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial.
    Usall J, Huerta-Ramos E, Labad J, Cobo J, Núñez C, Creus M, Parés GG, Cuadras D, Franco J, Miquel E, Reyes JC, Roca M, RALOPSYCAT Group.
    Schizophr Bull; 2016 Mar 21; 42(2):309-17. PubMed ID: 26591005
    [Abstract] [Full Text] [Related]

  • 11. Raloxifene: a review of its use in postmenopausal osteoporosis.
    Clemett D, Spencer CM.
    Drugs; 2000 Aug 21; 60(2):379-411. PubMed ID: 10983739
    [Abstract] [Full Text] [Related]

  • 12. Effect of hormone therapy and raloxifene on serum VE-cadherin in postmenopausal women.
    Christodoulakos G, Lambrinoudaki I, Panoulis C, Papadias C, Economou E, Creatsas G.
    Fertil Steril; 2004 Sep 21; 82(3):634-8. PubMed ID: 15374707
    [Abstract] [Full Text] [Related]

  • 13. Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women.
    Teerlink T, Neele SJ, de Jong S, Netelenbos JC, Stehouwer CD.
    Clin Sci (Lond); 2003 Jul 21; 105(1):67-71. PubMed ID: 12625833
    [Abstract] [Full Text] [Related]

  • 14. Veralipride for hot flushes induced by a gonadotropin-releasing hormone agonist: a controlled study.
    Vercellini P, Sacerdote P, Trespidi L, Manfredi B, Panerai AE, Crosignani PG.
    Fertil Steril; 1994 Nov 21; 62(5):938-42. PubMed ID: 7926138
    [Abstract] [Full Text] [Related]

  • 15. Effects of oral raloxifene on serum estradiol levels and other markers of estrogenicity.
    Reindollar R, Koltun W, Parsons A, Rosen A, Siddhanti S, Plouffe L, Study Group on the Effects of Raloxifene HCI With Low-Dose Premarin Vaginal Cream.
    Fertil Steril; 2002 Sep 21; 78(3):469-72. PubMed ID: 12215319
    [Abstract] [Full Text] [Related]

  • 16. [What can we expect of raloxifene in the treatment of postmenopausal osteoporosis--views of a gynecologist].
    Chmel R, Rob L, Strnad P.
    Ceska Gynekol; 2002 Jul 21; 67(4):187-91. PubMed ID: 12373918
    [Abstract] [Full Text] [Related]

  • 17. Effects of a long-term treatment with raloxifene on insulin sensitivity in postmenopausal women.
    Lasco A, Gaudio A, Morabito N, Previti M, Mileto A, Frisina N, Cucinotta D.
    Diabetologia; 2004 Mar 21; 47(3):571-574. PubMed ID: 14762655
    [Abstract] [Full Text] [Related]

  • 18. Effect of raloxifene on activated protein C (APC) resistance in postmenopausal women and on APC resistance and homocysteine levels in elderly men: two randomized placebo-controlled studies.
    Duschek EJ, Neele SJ, Thomassen MC, Rosing J, Netelenbos C.
    Blood Coagul Fibrinolysis; 2004 Oct 21; 15(8):649-55. PubMed ID: 15613919
    [Abstract] [Full Text] [Related]

  • 19. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.
    Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD, MORE Investigators (Multiple Outcomes of Raloxifene Evaluation).
    JAMA; 2002 Feb 20; 287(7):847-57. PubMed ID: 11851576
    [Abstract] [Full Text] [Related]

  • 20. Carotid artery intima-media thickness after raloxifene treatment.
    Mack WJ, Dhungana B, Dowsett SA, Keech CA, Feng M, Li Y, Hodis HN.
    J Womens Health (Larchmt); 2007 Apr 20; 16(3):370-8. PubMed ID: 17439382
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.